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Antibodies specific for the β1-adrenergic receptor are found in patients 
with chronic heart failure of various etiologies. From work presented in 
this issue of the JCI (see the related article beginning on page 1419), we 
can now infer that these antibodies actually contribute to the pathogenesis 
of chronic heart failure. This commentary discusses mechanisms by which 
these antibodies may engender cardiomyopathy.
Do anti–β-adrenergic receptor (anti–β-AR) 
antibodies play a role in the pathogenesis 
of chronic systolic heart failure (CHF)? 
This question emerged almost 30 years 
ago (1), when antibodies with β-adren-
ergic stimulating (agonist) activity were 
discovered in the serum of patients with 
Chagas disease, one of the most common 
causes of CHF worldwide (2). Since that 
time, IgGs with agonist activity for the 
β1-adrenergic receptor (β1-AR) have been 
found in sera not only from patients with 
Chagas disease, but also from patients 
with idiopathic dilated cardiomyopathy 
(3) as well as ischemic (4) cardiomyopathy. 
Whether these antibodies merely correlate 
with myocardial inflammation that leads 
to CHF, result from myocardial inflam-
mation, or actually contribute to the 
pathogenesis of CHF could not be ascer-
tained — until now. In this issue of the JCI, 
Jahns et al. employed isogenic injections 
of anti–β1-AR antiserum in inbred rats to 
produce a cardiomyopathy that appears 
to be non-inflammatory (5). In so doing, 
these authors conclusively demonstrated 
that agonistic, anti–β1-AR IgG — by itself 
— is sufficient to engender the sort of 
myocardial dysfunction characteristic of 
CHF. This finding fundamentally advanc-
es our understanding of CHF. However, 
it should not really surprise us, because 
it represents a logical extension of diverse 
but congruent investigations conducted 
over several decades.
To provide historical and mechanistic 
perspectives for the elegant work of Jahns 
et al., we address several questions that 
relate their work to contemporary concepts 
of β1-AR pathophysiology: How might IgG 
activate the β1-AR, and how could chronic 
β1-AR activation result in cardiomyocyte 
toxicity? What molecular mechanisms 
regulate the β1-AR when it is chronically 
stimulated by IgG or other agonists, and 
how might these mechanisms affect the 
pathogenesis of CHF? Lastly, how can 
these perspectives elucidate the therapeu-
tic efficacy of β-AR antagonists, or “beta 
blockers,” in CHF?
Activation of cardiac β1-ARs
The β1-AR constitutes approximately 80% 
of the cardiac β-AR complement. Like the 
β2-AR (with 54% overall homology), the 
β1-AR is a seven-membrane–spanning 
receptor, with three extracellular polypep-
tide sequences (“loops”) connecting the 
transmembrane α helices (Figure 1). With 
their intracellular domains, the β-ARs cou-
ple to the stimulatory heterotrimeric GTP-
binding protein (Gs). Activation of the 
β1-AR requires a specific receptor confor-
mation — one that is stabilized by agonist 
(and, apparently the binding of certain 
IgGs to the second extracellular loop; ref. 
5). It also appears that β1-AR dimerization 
(6, 7) may be involved in receptor activa-
tion (and may underlie the agonist prop-
erties of anti-β1-AR antibodies observed 
in CHF patients and rats). Stimulation of 
β-ARs engenders a cascade of consequent 
activation: first Gs, then adenylyl cyclase 
(which forms cAMP), then the cAMP-
dependent protein kinase (PKA). Activat-
ed PKA subsequently phosphorylates mol-
ecules critical for regulating sarcoplasmic 
[Ca2+] (8) — thereby increasing cardio-
myocyte inotropy, chronotropy, and lus-
itropy. Activation of Gs can also increase 
L-type Ca2+ channel currents directly (9, 
10) (Figure 1). Over the last few years, this 
time-honored scheme has been modified 
in ways that illuminate the β1-AR-specific 
findings of Jahns et al. (5).
Genetic and pharmacologic approaches 
have demonstrated that the β1-AR plays 
the predominant role in mediating cardiac 
inotropic and chronotropic responses to 
catecholamines (8). Cardiac preparations 
from β1-AR knockout mice fail to augment 
contractility or their rate of contraction in 
response to isoproterenol, which stimu-
lates both β1- and β2-ARs (11). Remark-
ably, β1-AR knockout hearts have almost 
the same β2-AR density as cognate wild-
type controls, and can demonstrate con-
tractile responses equivalent to controls 
— when contractility is augmented directly 
via adenylyl cyclase rather than via β-ARs 
(11). Even isoproterenol-induced adenylyl 
cyclase activity in cardiac homogenates is 
mediated overwhelmingly via the β1-AR, in 
a manner disproportionate to the relative 
densities of β1- and β2-ARs (11). The fail-
ure of cardiac β2-ARs to promote cAMP 
production to a degree commensurate 
with their expression level may be attrib-
utable to a signaling property that the car-
diac β2- and β1-AR do not share: the ability 
to activate both the inhibitory heterotri-
meric G protein (Gi) and Gs (12, 13). (A 
β1-AR subtype-specific intracellular bind-
ing protein appears to prevent β1-AR/Gi 
coupling [ref. 14].) In human subjects, 
β2-AR–selective agonists have been used 
to augment left ventricular inotropy (15). 
However, a large fraction of this inotropic 
effect is mediated by β1-ARs, and the role 
of β2-ARs in this process may be largely to 
augment norepinephrine release from car-
diac sympathetic neurons (15).
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Excessive β1-AR activation yields 
cardiomyocyte toxicity
Excessive isoproterenol stimulation has 
long been known to produce cardiomyocyte 
toxicity, myocardial scarring, and CHF (16, 
17). More recently, chronic administration 
of submaximal isoproterenol doses has also 
been shown to produce cardiomyopathy, 
independent of myocardial scarring 
(18). That this isoproterenol-induced 
cardiomyopathy results primarily from 
β1-AR activation can be inferred from the 
β1-AR knockout mouse studies discussed 
above (11), as well as from a host of in vitro 
studies with rodent cardiomyocytes (13, 19). 
Further evidence that chronic β1-AR hyper-
stimulation causes cardiomyocyte toxicity 
has emerged from studies with transgenic 
mice displaying modest (∼15-fold), cardiac-
specific overexpression of the β1-AR: these 
mice not only possessed enhanced β1-AR 
activity, but also developed cardiomyopathy 
by age 4–9 months (20). In contrast, trans-
genic mice overexpressing the β2-AR at 
higher absolute levels failed to develop any 
cardiomyopathy by this age (21).
The particular signaling pathways 
responsible for β1-AR–induced cardiomyo-
cyte toxicity remain somewhat enigmatic. 
Increasing cardiomyocyte PKA activity 
by as little as 2.4-fold can engender CHF 
(22), and cardiomyocyte overexpression 
of Gαs engenders CHF (23). However, 
overexpression of adenylyl cyclase type VI 
(which also augments cardiomyocyte cAMP 
levels) not only avoids CHF but also can 
alleviate CHF in the Gαq-overexpressing 
mouse (24). In addition, β1-AR–promoted 
cardiomyocyte apoptosis can result from 
Ca2+/calmodulin-dependent protein kinase 
activity, independently from the PKA path-
way (19). The diverse studies delineating 
molecular mechanisms responsible for 
β1-AR–promoted cardiomyocyte toxicity 
have been reviewed recently (8). In light 
of these data, it is intriguing that levels of 
plasma norepinephrine (which activates 
the β1-AR, like the anti–β1-AR IgG of Jahns 
et al. [ref. 5]) have been directly and inde-
pendently associated with CHF mortality 
in human subjects (25).
Figure 1
Schema for β1-AR–mediated cardiomyocyte stimulation and β1-AR desensitization. The seven-membrane-spanning β1-AR is stimulated by the 
physiologic agonist norepinephrine or by IgG specific for the receptor’s second extracellular loop (ECII) (in CHF subjects). The stimulated β1-AR 
then activates the heterotrimeric Gs, which dissociates into its Gαs* and Gβγ substituents. The Gαs* activates both adenylyl cyclase (AC), which 
catalyzes cAMP formation, and the L-type calcium channel (L), which then permits Ca2+ to enter the cardiomyocyte. This Ca2+ can both aug-
ment contractility and, on a slower time scale, promote cardiomyocyte apoptosis by activating Ca2+/calmodulin kinase II (CaMK II). The cAMP 
produced by adenylyl cyclase activates PKA, which subsequently phosphorylates (P) numerous substrates important to sarcoplasmic [Ca2+] 
regulation: the L-type Ca2+ channel, the ryanodine receptor (RyR), and phospholamban (PLB). The net effect of this activity in the short term 
is to augment sarcoplasmic [Ca2+] and contractility. (In the long term, this activity engenders cardiomyocyte toxicity.) The activated β1-AR is 
desensitized when it is phosphorylated by PKA (not shown) and by GRK2, the cellular expression of which increases with chronic β1-AR stimula-
tion. Translocation of GRK2 from the sarcoplasm to the sarcolemma requires Gβγ subunits, and this translocation is inhibited when GRK2ct is 
expressed heterologously in cardiomyocytes. Asterisks denote activated proteins.
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Regulatory mechanisms for 
subduing the β1-AR signaling system
In the face of persistent β1-AR hyperstimu-
lation (either in CHF or experimental sys-
tems), both receptor-based and non-receptor 
counter-regulatory mechanisms are engaged 
in the cardiomyocyte — perhaps to bridle 
cellular toxicity. These mechanisms result 
in approximately 50% downregulation 
of the β1-AR itself (26) (through mecha-
nisms that appear to involve PI3K [ref. 
27]), a decrease in adenylyl cyclase activity, 
and upregulation of the multifunctional 
Gi (which can inhibit adenylyl cyclase) 
(23). In addition, myocardium from CHF 
patients demonstrates a two- to threefold 
upregulation of G protein–coupled receptor 
kinase-2 (GRK2) (26), which phosphorylates 
and desensitizes the β1-AR (28, 29). This 
upregulation of GRK2 even precedes the 
onset of left ventricular failure in mice with 
transgenic myocardial overexpression of 
calsequestrin (30). Although these “desensi-
tizing” mechanisms are insufficient to pre-
vent CHF, some of them may, paradoxically, 
contribute to CHF pathophysiology. Perhaps 
the most thoroughly studied of these cases is 
the role of GRK2.
Relieving excessive β1-AR 
desensitization
Inhibition of cardiomyocyte GRK2 activity 
has been shown to ameliorate CHF in sev-
eral mouse models, including deficiency of 
muscle LIM protein (31) and myocardial 
calsequestrin overexpression (32). GRK2 
inhibition in these studies was achieved by 
transgenic myocardial overexpression of a 
polypeptide that comprises the carboxyl-
terminal third of GRK2. This molecule, 
termed GRK2ct, inhibits GRK2 activity on 
receptors by binding to the heterotrimeric 
G protein βγ subunits required for GRK2 
recruitment to the receptors (33) (Figure 
1). Because “GRK2ct therapy” presumably 
does not alter the fundamental cardiomyo-
cyte problems leading to myocardial dys-
function in these mouse models, its success 
points to the possibility that CHF-related 
enhancement of cardiomyocyte GRK2 activ-
ity may itself be maladaptive, and contribute 
to the pathogenesis of CHF. Remarkably, 
GRK2ct-expressing myocardium demon-
strates attenuation of CHF-related GRK2 
upregulation (31), β1-AR downregulation 
(31), and β1-AR/adenylyl cyclase desensiti-
zation (31, 32). In interpreting these data, 
however, it is important to note that GRK2ct 
binds a large variety of Gβγ subunits as well 
as phosphatidylinositol 3,5-bisphosphate 
(33). These binding activities could, beyond 
inhibiting GRK2, also contribute to the 
effects observed with GRK2ct (27, 34).
β-AR antagonists: possible 
mechanisms underlying  
therapeutic efficacy
Improvements in myocardial contractility, 
exercise tolerance, and mortality have been 
observed in CHF patients treated chroni-
cally with the β-AR antagonists metoprolol, 
bisoprolol, and carvedilol (35). This clinical 
improvement cannot depend upon reversal of 
β1-AR downregulation, since carvedilol does 
not promote such a reversal (35). Moreover, 
this clinical improvement seems unlikely to be 
mediated through β1-ARs at all, since it can be 
observed under conditions precluding agonist 
stimulation of β1-ARs (36). However, probably 
because it diminishes toxic hyperstimulation 
of the β1-AR by elevated sympathetic tone, 
prolonged β-AR antagonist therapy reduces 
cardiomyocyte apoptosis in CHF (37) and 
effects a partial recovery of CHF-associated 
derangements in gene expression (38, 39) and 
PKA-mediated hyperphosphorylation of pro-
teins (40, 41), including those constituting 
the signaling and Ca2+-handling machinery 
downstream of the β1-AR. These “receptor-
distal” mechanisms can enhance myocardial 
performance despite ongoing β-AR antago-
nist occupancy (36).
As a specific example of how mechanisms 
distal to the receptors can affect cardio-
myocyte function, let us again consider the 
role of GRK2 in CHF. Bisoprolol (42) and 
carvedilol (43) have been used in animals to 
reduce GRK expression. (We should note that 
bisoprolol was used by Jahns et al. to abolish 
the adenylyl cyclase response to anti–β1-AR 
IgG [ref. 5].) Because GRK2 can desensitize 
a multitude of heptahelical receptors (33), 
reduced GRK2 levels could enhance signal 
transduction, and thus inotropy, evoked by 
heptahelical receptors other than the (antag-
onist-occupied) β1-AR, such as endothelin 
receptors (44). From the perspective of this 
hypothesis, it is intriguing that metoprolol 
and GRK2ct reduced calsequestrin-associated 
cardiomyopathy in a synergistic manner (32).
Perspectives
From decades of CHF investigations, we 
should indeed have expected that agonistic, 
anti–β1-AR antibodies would promote the 
development of heart failure. Now that 
Jahns et al. have provided an important 
proof of principle (5), we have another 
excellent reason to increase the clinical use 
of β-AR antagonist therapy in CHF of all 
causes. Whether immunoadsorption of 
anti–β1-AR antibodies (45) will provide 
CHF patients with benefits beyond those 
obtainable from β-AR antagonists alone, 
however, remains to be determined.
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Dissecting the functional role of different  
isoforms of the L-type Ca2+ channel
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There currently exist a great number of different mouse lines in which the 
activity of a particular gene of interest has been inactivated or enhanced. 
However, it is also possible to insert specific mutations in a gene so that 
the pharmacological sensitivity of the gene product is altered. An example 
of such an approach shows how the abolition of the sensitivity of an L-type 
Ca2+ channel isoform to dihydropyridines allows the investigation of the 
physiological role of these channels in different tissues (see the related 
article beginning on page 1430).
The LTCC family
L-type Ca2+ channels (LTCCs) are formed 
by different pore-forming α1 subunit 
isoforms named Cav1.1, Cav1.2, Cav1.3, 
and Cav1.4 associated to auxiliary subunits 
(α2-δ, β, and γ) (1). The common pharma-
cological hallmark of all native and recom-
binant LTCCs is their sensitivity to dihy-
dropyridines (DHPs). However, the small 
differences among the LTCC α1 isoforms 
in their affinity for DHPs (agonists and 
antagonists) have limited the study of the 
functional role of these channels in various 
tissues, including the cardiovascular sys-
tem, the brain, and the endocrine glands.
In this issue of the JCI, Sinnegger-Brauns 
and coworkers report that they have devel-
oped a new mouse model resulting from 
a knock-in mutation of the CaV1.2 volt-
age-dependent LTCC subunit which abol-
ishes the sensitivity of the channel to DHP 
(referred to herein as the CaV1.2DHP–/– 
mouse) (see Figure 1) (2). Since Cav1.2 is 
Nonstandard abbreviations used: dihydropyridine 
(DHP); L-type Ca2+ channel (LTCC).
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